The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

Conditions

  • Parkinson Disease

Intervention

  • AAV2-GDNF gene therapy
  • control surgery

Principal Investigator

  • Boling, Warren

Sponsor

  • Asklepios BioPharmaceutical (AskBio)

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 09/10/2026. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.